With new treatment options set to launch in the treatment of type 2 diabetes over the next few years, knowing how they will fair and whether or not that type of treatment will succeed is imperative if you wish to successfully enter this competitive market.
Our new type 2 diabetes pipeline analysis looks at all treatments from early-phase opportunities through to late-stage development, with individual forecasts for each product included in the accompanying datapack. We have validated our pipeline candidates against a variety of sources including Citeline, Medtrack, BioMedTracker, and company websites.
This new report includes interactive 20-year forecasts of type 2 diabetes pipeline treatments. You are able to drill down to analyse what factors are driving this growth across the different treatments and what are the areas of focus across the indication area.
Fill out the form now to download your exclusive sneak peek into this market leading report >>
HIGHLIGHTS
- Xultophy will be the first glucagon-like peptide-1 agonist and basal insulin fixed-dose combination product to reach the type 1 diabetes market
- The drug’s robust efficacy data mean it will be well received by phsicians
- Evaluation of the commercial potential of early-phase type 2 diabetes pipeline with individual forecasts
Fill out the form now to download your exclusive sneak peek into this market leading report >>
If you’re already a subscriber to Datamonitor Healthcare, click here to access the full report.